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Abstract. Guiding legislation and associated bureaucracy for the ethical review of clinical trials observational 
studies and food related research play an important role in the competitiveness of a nation in the face of tough 
global competition to attract sponsors and investigators. This is of particular relevance in the case of multi-
centre trials and multidisciplinary research. Accordingly, in this report we tried to gather in-depth knowledge 
of the current role and practices of ethics committees nationwide in both clinical and research settings. This 
mini-review aims to describe the formulation and organization of ethical committees in Italy in order to pro-
vide a focus for deliberations on ethical issues in medical and scientific research in line with human rights, as 
set out in the European Union charter. Furthermore, we evaluated the impact of an institution’s ethical com-
mittee intervention on reducing the time required to obtain an opinion from Research Ethics Committees by 
guiding investigators in addressing ethical issues in their proposed studies.  (www.actabiomedica.it)
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Introduction
Bioethics is a discipline dealing with ethical issues 
in biomedical and biological research. With the ongo-
ing advance of science and technology, the concerns 
related to safety and security of human subjects have 
increased tremendously. This requires that biomedical 
research and health care activities, as well as proposed 
scientific activities, must be reviewed by independent 
authorities according to national, supranational and 
international legislation. This required the establish-
ment of ethical committees (ECs) to ensure that re-
search and health care practices are carried out in an 
ethically acceptable manner.
Ethics Committees (ECs) are independent, mul-
tidisciplinary, non-profit bodies. They are constituted 
to evaluate clinical experimentation and research in-
volving human subjects and routine patient care from 
an ethical and scientific point of view, in order to en-
sure that these abide by the ethical standards set by 
national and international guidelines (1). These com-
mittees are deployed to analyse the ethical concerns 
related to patient care or research involving human 
subjects (2). Depending upon their specific roles, the 
ethical committees are of two types: Research Ethics 
Committees (RECs), and Clinical Ethics Commit-
tees (CECs) (3,4). RECs deal with the evaluation of 
research projects and protocols so as to protect the 
rights, safety and wellbeing of human subjects in-
volved in clinical research and trials, while CECs are 
responsible for addressing the ethical issues related to 
daily clinical practice, bioethics training, and the de-
velopment of ethical guidelines (3,4).
History and importance of Ethical Committees
The establishment of ethical committees has been 
a relatively short journey. In the early second half 
of the 20th century, review bodies started to emerge, 
mainly as a form of self-regulation within the medical 
profession, and often in an ad-hoc form in response to 
specific problems. However, in past decades Research 
Ethics Committees (RECs) have been established in 
most European countries and worldwide as permanent 
and independent bodies (4,5). As such they form, at 
least in Europe and other western countries, the core 
of a robust infrastructure which monitors and reviews 
research projects. Several supporting initiatives have 
been also promoted e.g. by the World Health Organi-
zation, in establishing the Global Network of WHO 
Collaborating Centres for Bioethics (https://www.
who.int/ethics/partnerships/global_network/en/).
The history of the formation of ethics committees 
dates back to the 1960s, when the US National Insti-
tutes of Health established a policy regarding the ethi-
cal review of all research projects submitted to the US 
Public Health Service for funding (5). This initial act 
stimulated debates which took place on ethical con-
cerns regarding clinical studies involving human sub-
jects. These debates resulted in the National Research 
Act 1974, with the subsequent establishment of the In-
stitutional Review Board (IRB) system to oversee clin-
ical research practices involving humans (6). Further 
developments led to the establishment of a National 
Commission for the Protection of Human Subjects of 
Biomedical and Behavioural Sciences, to safeguard in-
dividuals participating in clinical trials and to develop 
guidelines for biomedical research. The Commission 
mandated that all research protocols involving humans 
must seek approval from the IRB. At the same time, 
the President’s Commission for the Study of Ethical 
Problems in Medicine and Behavioural Research was 
established to examine ethical issues involving health 
care services and professionals, which led to organiza-
tion of clinical ethics committees (CECs) for address-
ing ethical issues of clinical practice (2,6).
Research ethics in Europe
Meanwhile in 1964 in Helsinki, Finland, the 
World Medical Association adopted a declaration on 
research ethics as a reaction to malpractices revealed 
during the Nuremberg trials (7). Since then, this dec-
laration has been extensively reviewed. However, the 
main focus and the central ideas remain unchanged 
(8). The declaration sets out ethical principles for bio-
medical practices and research involving human sub-
jects, the basic principle being the prioritization of the 
safety and well-being of human subjects, followed by 
principles for medical research and, additionally, for 
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medical research combined with medical care (8). The 
EU regulatory framework emphasizes the explicit EU 
commitment to human rights, illustrated by the Ovie-
do Convention (9) which was adopted by the Council 
of Europe in 1997, and also by the European Char-
ter of Fundamental Rights (10). This convention ad-
dresses the ethical issues raised in research within the 
framework of human rights protection (9). It sets out 
principles to ensure the welfare of human beings, and 
to ensure informed consent and privacy (9).
Ethics is given the highest priority in EU funded 
research: all the activities carried out under Horizon 
2020 must comply with ethical principles and relevant 
national, EU and international legislation (see e.g. 
https://ec.europa.eu/programmes/horizon2020/en/
h2020-section/ethics) The most common ethical issues 
include those relating to the involvement of children, 
patients, vulnerable populations, the use of human em-
bryonic stem cells, privacy and data protection issues, 
research on animals and non-human primates, misuse/
malevolent use, food security and safety, impact on the 
environment, etc. It also includes the avoidance of any 
breach of research integrity, which means, in particular, 
avoiding fabrication, falsification, plagiarism or other 
research misconduct. The EU ensures that the research 
it funds complies with core ethical values in all phases 
of research. Even though research ethics are more es-
tablished in medical research, it is equally pivotal for 
all scientific domains. For that reason, professional and 
academic associations formulate policies and guide-
lines with ethics codes, adapted to their specific re-
search domains.
Recently, the EU has implemented its Regulation 
536/2014 on clinical trials (11), aiming to increase the 
efficiency and rapidity of the procedures for approving 
trials, simplifying sponsors’ obligations and guarantee-
ing public access to trial-related data. The regulations 
attribute to the ECs the freedom to organize their 
activities in accordance with each EU member state’s 
legislation. De facto, Regulation 536/2014 has reduced 
the number of ECs and increased the workload in clin-
ical trials, and the activity addressing ethical issues in 
every-day clinical practice is further diminished (12).
Table 1. Number of Research Ethic Committees (RECs) and accountability of RECs at different levels in EU countries (13)
Country Number of RECs Type of REC-Accountable to whom
UK 80+51 for non clinical trial of an investigational medicinal product.









Outside hospital—institute where situated
Bulgaria 103
Central REC on drug trials—Ministry of Health
Central REC on research ethics— Ministry of Education and 
Science
Local REC—central REC
Cyprus 3+1 central Central REC—Ministry of HealthLocal—none
Czech Republic 9 multicentre, 100 local Central REC—noneLocal REC—none
Denmark 11 Central REC—noneRegional REC—central REC
(continued on next page)
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Table 1 (continued). Number of Research Ethic Committees (RECs) and accountability of RECs at different levels in EU countries (13)
Country Number of RECs Type of REC-Accountable to whom
Estonia 2 Regional RECs—none





Germany 53 Central REC—Federal ChancellorLocal REC—institution where situated
Greece One in each region and hospital+1 central
Central REC—Ministry of Health
Regional and local RECs—none
Hungary Several regional and local+1 central
Central REC—Ministry of Health
Regional REC—central REC
Local REC—regional REC
Ireland 13 Local REC—Ethics Committees Supervisory Body
Italy 90
National bioethics committee—Prime Minister
Central REC—Ministry of Health
Local REC—none
Latvia 4 regional+1 central Central REC—noneRegional REC—central REC
Lithuania 3 Central REC—Ministry of HealthRegional REC—central REC
Luxembourg 1 No information available
Malta 3 local+1 central Central REC—universityLocal RECs—institution where situated
Netherlands 30 regional+1 central Central REC—Minister of Health and ParliamentRegional REC—none
Poland 52+1 central Central REC—noneLocal RECs—central REC
Portugal Several local+1 central Central REC—Minister of HealthLocal REC—institution where situated
Romania 1 Central REC—Ministry of Health
Slovakia 8 regional+ about 60 local+1 central Central REC—Minister of HealthLocal REC—Minister of Health
Slovenia Several local+1 central Central REC– noneLocal REC—central REC
Spain 136 Local RECs—none
Sweden 6+1 central Central REC—noneRegional RECs—none
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Ethical Committees in Italy
Historical milestones 
The situation of ethics committees (ECs) in Italy 
is at a critical point, because of a number of factors 
emerging from new technical and scientific advances, 
new legislative requirements and lack of harmoniza-
tion of procedures. To look into the issue in greater 
depth, it is important first to understand the establish-
ment and organization of ethical committees in Italy. 
The organization of ECs is quite different in Italy to 
the rest of the EU. The first EC was created in 1973, 
with the aim of ensuring that research for new medical 
treatments was “for a person and with a person, never 
on a person” (14). In the 1980s, there were few bod-
ies in Italy that could be regarded as ECs (regionally, 
in public bodies or in universities). It was only on 28th 
March 1990 that the Italian National Bioethics com-
mittee was established, according to a decree signed by 
the President of the Council of Ministers (15). 
The Italian National Bioethics Committee (NBC)
The NBC consists of 40 members. including a 
Chairman, two vice-Chairmen and experts from various 
medical specialties such as biology, jurisprudence, psy-
chology and philosophy. These members are appointed 
for a period of three years, with membership being in-
terdisciplinary and diverse, thus bringing together dif-
ferent experties on a single platform. The Committee 
holds monthly plenary sessions and has five sub-com-
mittees focused on specific areas, dealing with bioethical 
issues in the human genome and biotechnologies, arti-
ficial insemination, biomedicine, protection of critically 
ill subjects, moral epistemology and bioethics training. 
The tasks assigned to these committees are to give opin-
ions, prepare legislative acts and address ethical and le-
gal problems associated with the impact of scientific and 
technological progress on human life. The NBC also 
maintains relations with Ethics committees and legis-
lative bodies at European and international levels (16).
Regulatory framework of Ethics Committees in Italy
A fundamental step for clinical regulation in Italy 
was the implementation of good clinical practice in 
the conduct of clinical trials on medicinal products for 
clinical use (16). This was achieved through Legisla-
tive Decree No 211 of 24 June 2003 (the latest version 
of the Helsinki Declaration, the Oviedo Convention, 
good clinical practice standards and the guidelines on 
the evaluation of the effectiveness of clinical trials up-
dated by the European Agency for the Evaluation of 
Medicinal Products). According to Article 2(1)(m) of 
the Decree, an EC is “an independent body consisting 
of healthcare professionals and non-medical members, 
whose responsibility it is to protect the rights, safety and 
wellbeing of human subjects involved in a trial and to 
provide public assurance of that protection […]” (17).
Regional and local Ethics Committees
In last two decades, regional and national ECs 
were established in Italy within hospitals, university 
polyclinics, biomedical research bodies and institu-
tions. According to Article 1 of Legislative Decree No 
211 regarding clinical trials on medicinal products, the 
ECs should verify the applicability of proposed trials 
by critically evaluating their rationale, the relevance of 
protocols (objectives, design, operation, result evalua-
tion), the competence of researchers, and should assess 
all ethical aspects, with respect to informed consent 
while ensuring protection of privacy in the use of bio-
logical samples. Moreover, “The competence of each 
Committee may concern, in addition to clinical trials 
on medicinal products, any other issue they might be 
entrusted with according to international practices, 
namely the use of medicines and medical devices, sur-
gical and clinical procedures or procedures related to 
studies on food products on humans” (Law 8 Novem-
ber 2012, No. 189, Art. 12) (18).
The organizational structure of regional ECs is 
represented by the Regions. Each Ethics Commit-
tee is in charge of one or more provinces, in order to 
comply with the standard of one Committee per mil-
lion inhabitants, without prejudice to the possibility of 
providing an additional Ethics Committee, competent 
to act in one or more scientific hospitalization and care 
institutions (Law 8 November 2012, n. 189, Art. 5). 
Some of the ECs have a national mandate that identi-
fies their expertise in a particular area. Amongst these 
are the Ethics Committees of the National Institute 
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of Health (Istituto Superiore di Sanità, ISS) and the 
“Celio” Military Hospital (Decision of Lazio Region 
of June 12, 2013) (19).
Further developments in regional and National Ethics 
committees in Italy
The latest EC guideline is the Ministerial Decree 
of February 8, 2013 (20) which specifies that ECs are 
independent bodies that ensure the rights, safety and 
wellbeing of subjects enrolled in clinical trials, and 
evaluate those trials on scientific, ethical and procedural 
bases, thus guaranteeing public protection. Moreover, 
this Decree allows the ECs to promote consultation on 
ethical matters pertaining to scientific and clinical ac-
tivities in the case where these have not been assigned 
to any other specific bodies. Hence, the overall objec-
tive is to promote human values and to safeguard the 
self-esteem and value of human subjects. In addition, 
ECs can propose bioethics training for health profes-
sionals. Furthermore the legislation in 2014 (EU) No 
536/2014 ; Article 8 (“Decision on the clinical trial”) 
states that: “Each Member State concerned shall noti-
fy the sponsor through the EU portal as to whether the 
clinical trial is authorised, whether it is authorised sub-
ject to conditions, or whether authorisation is refused, 
notification shall be done by way of one single deci-
sion” (21). This resulted in a national debate on reduc-
ing the number of ECs. As a result, a gradual decline 
in the number of ECs in Italy from 243 in 2012 to 91 
in 2014 and 90 in 2019 (22) took place. Furthermore, 
Law No 3 of 11 January 2018 (23) promoted a further 
reduction in the number of ECs. Two decrees issued 
by the Minister of Health following this law required 
the identification of a maximum of 40 local ECs and 3 
national ECs, of which one would be reserved for the 
paediatric environment. However, implementing this 
reform is difficult in practical terms, as legislation for 
establishing local ECs and national ECs has still not 
been enacted. A further provision of this law was the 
establishment of an Italian Medicine Agency (AIFA) 
and a National centre for the coordination of regional 
ethics committees for clinical trials of medicines and 
medical devices for human use (23). 
Following an EU regulation, the NBC suggested 
that CECs should be given legislative and administra-
tive attention. A further Legislative Decree No 52 of 
14 May 2019 was issued for the ‘Implementation of 
the designated powers to review and reform the regu-
latory provisions in relation to clinical trials on medici-
nal products for human use, under Article 1(1) and (2) 
of Law No 3 of 11 January 2018 (23)’. Certain provi-
sions in this Decree might have a significant impact on 
clinical trials. For instance, sponsors are permitted to 
transfer data and results from non-profit trials for reg-
istration purposes. Until now, the use of data obtained 
from non-profit trials for registration purposes has 
been restricted. The sponsor or transferee is, however, 
required to pay and to reimburse the direct and indi-
rect costs incurred in the trial. Moreover, if the study is 
further reclassified as profit-making, they have to pay 
the corresponding charges, including any returns from 
the exploitation of intellectual property. A Decree of 
the Minister of Health was enacted on 31 October 
2019 to stipulate measures intended to enable and sup-
port the performance of non-profit clinical trials and 
observational studies, as well as to identify measures 
for ensuring coordination between public and private 
sponsors for clinical trials set up for post-marketing 
surveillance of medicinal products. That Decree also 
established an order, enacted by the AIFA, to identify 
suitable procedures to assure the independence of clin-
ical trials, ensuring that no conflict of interest should 
arise in the assessment of subsequent applications.
Ethical guidelines for observational studies
In the health sciences, observational studies are 
those studies in which an investigator considers the 
variables of interest without his actions in any way 
influencing the condition of the subject or subjects 
studied. Observational studies are different from ex-
perimental studies, in the sense that in these studies no 
intervention other than recording, classifying, count-
ing and analysing of data takes place. In observational 
studies the investigator has no control over the study 
variables and merely observes outcomes. Most obser-
vational research is epidemiological or health services 
research, but some observational studies, include case 
series and case studies, are conducted by clinicians in 
personal care settings (24).
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Observational studies can be classified into case 
control studies, cohort studies, cross sectional studies, 
case reports, case series, and descriptive studies which 
add generalizable knowledge about health or disability 
issues. These studies play an important role in ensur-
ing the public interest in a safe environment and in safe 
and effective health and support services. These studies 
might examine the exposure of humans to chemicals in 
the environment or to medicines resulting in diseases 
and disorders. In addition, these studies are used to 
identify any gaps in health and support service provi-
sion, and this obliges service providers to inform con-
sumers that studies of this type are of utmost impor-
tance in improving the quality of the health and support 
services. They should also give consumers details of the 
measures taken to protect participants from harm (24).
Ethical requirements and regulations pertaining to 
observational studies 
Investigators conducting, or involved in conduct-
ing, observational studies are responsible for ensuring 
that these studies meet ethical standards. Observa-
tional studies might or might not require informed 
consent and rigorous EC review. When there is more 
than one investigator, the principal investigator has 
the overall responsibility for the ethics of the activity. 
The ethical guidelines regarding observational studies 
generally vary depending upon the type of study, and 
might not be subject to EC review at all. For that rea-
son clear guidelines for such studies are scarce. Cur-
rently, approval by ethics committee is mandatory for 
all research in Canada, including the analysis of patient 
records (25). However, no such requirement exists for 
retrospective studies in, for example, Turkey (26).
Current legislative provisions in Italy pertaining 
to observational studies are the following:
1) The Italian Ministry of Health circular n. 6, 
2002, which defines non-interventional (observation-
al) trials (27)
2) The Italian Legislative Decree n. 211/2003 on 
clinical trials of medicinal products, which also gives 
a definition of the “non-interventional” trial (observa-
tional study) (17)
3) The 20 March 2008 ruling of the Italian Drug 
Agency (Agenzia Italiana del Farmaco, AIFA) which 
gives guidelines for the classification and conduct of 
observational drug trials (28).
Since the publication of the first Italian legisla-
tion, as mentioned above, considerable attention has 
been paid to defining and approving observational 
studies by the clinical and epidemiological research 
sector. Following the publication of these regulations, 
a significant increase in the number of observational 
(“non-interventional”) study protocols was submitted 
to ethics committees for evaluation in Italy. 
However, because there is no clear legislation in 
this area from the EU, the ECs have difficulty in de-
fining, interpreting and implementing existing regu-
lations. Under EU human rights legislation, it can 
be inferred that observational studies should ensure 
respect for and protection of people participating in 
these studies, with a fair distribution of the benefits 
and burdens. The study should be designed in such a 
manner that inclusion and exclusion criteria for par-
ticipants are fair. There should not be any discrimina-
tion on the base of age, sex, disability or religious or 
spiritual affiliation, except where it is essentially im-
portant to do so. Investigators should respect diversity 
among participants, and conduct honest and thought-
ful inquiry with rigorous analysis. Conflict of interest 
should be avoided in the case of multidisciplinary and 
multi-centre research.
Just as the registration of clinical trials has an eth-
ical and scientific rationale, registering observational 
studies at approved locations reduces duplication, en-
sures monitoring of projects with respect to ethical 
guidelines, provides global access to and improves the 
credibility of the information, and ensures transpar-
ency of research, thereby creating a knowledge bank. 
However, observational studies are prone to publica-
tion and reporting bias due to lack of regulations re-
garding registration and reporting. Hence, registration 
of these studies provides them with authenticity and 
rationale (29,30). 
Presently, ClinicalTrials.gov in Canada and US 
(31,32) and the European Union electronic Register of 
Post-Authorisation Studies (EU PAS Register) in the 
EU are publicly available for the registration of post-
authorisation studies, in order to improve the trans-
parency of observational research (33). Over the past 
few years, the number of observational studies regis-
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tered per year has increased, and observational studies 
now represent about 15% of all studies on ClinicalTri-
als.gov. Approximately half of these studies are from 
North America followed by Europe (20%) and Asia 
(13%), where 85% of these are funded by non-industry 
sources (31,34).
There is a considerable debate over the require-
ments of the EC committee for approval of observa-
tional studies. Some researchers are of the opinion that 
EC review is not required because these studies are not 
sensitive with respect to ethical concerns while, on the 
other hand, other researchers emphasise the need for 
EC review of each observational study. (35-38).
To harmonize the process of reporting of ob-
servational studies, in 2004, an international initia-
tive, Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE), was launched. 
STROBE provides complete guidelines on reporting 
observational studies such as study design, partici-
pants, and results However, ethical requirements and 
registration procedures are not addressed (39). 
The International Committee of Medical Journal 
Editors (ICMJE), along with specific international 
journals, however, has clearly stated that submitting 
publications based on observational studies requires 
ethical approval, or at least a letter from an EC if ethi-
cal approval is not required (40-44). 
Ethics in food research 
With the increasing world population and ex-
tensive urbanization, the production of enough food 
to feed everyone is a huge challenge, not only for 
agriculture research and industry but also for food 
and nutrition related research and industries. As this 
area is directly related to the wellbeing and safety 
of humans and involves the use of animals both for 
research and as a food source, there are ethical con-
cerns which are governed by relevant guidelines and 
procedures (45,46). Food and nutrition research is a 
diverse field with many aspects that raise ethical con-
cerns such as research and development of new prod-
ucts and processes (e.g. GMOs), consumer behaviour, 
health claims, supply chain, agricultural practices, food 
safety and security, sustainability, regulation, trade and 
emergency food aid. Ethics plays an important role in 
all these areas and frequently gives rise to questions 
and challenges concerning issues and practices in food 
related research. There are moral, cultural, social and 
spiritual values related to the personalization of food 
among various regions of the world, and this also re-
sults in ethical considerations when embarking on 
food related research (47).
Risks to humans, animals and the environment
General ethical principles in food research are 
the same as in other research arenas; they include per-
sonal safety and wellbeing, safeguarding the prestige 
and honour of participating human subjects, ensuring 
equal distribution of benefits, equity and justice, and 
informing participants about harms which might arise 
during experimental and non-experimental methods, 
including observational studies, interviews, web-based 
data collection (especially in the case of vulnerable 
groups such as children), exposure of participants to 
stressful and uncomfortable situations etc. In addition, 
while designing the study, the researchers should give 
thorough consideration to potential risks and to ethi-
cal issues related to society, animals and the environ-
ment, and should take necessary precautions to allevi-
ate and avoid adverse effects.
In case of research involving animals, research-
ers should ensure animal welfare and the three Rs for 
animal research i.e. replacement, reduction and refine-
ment, to keep their suffering to a minimum. Cell and 
tissue cultures should be used wherever possible, re-
placing animals. Endangered species or species at risk 
should be avoided. Biotechnological research, particu-
larly that involving GMOs, is of particular concern 
with respect to threats to the environment. Research 
in this area should be a balance between risk and ben-
efits (47,48).
Ethical considerations in food research methodologies 
and multidisciplinary research projects
Food research involves various methods. These 
may encompass but are not limited to research, equiv-
alent to medical research, which involves clinical tri-
als to check the safety of food in human subjects with 
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respect to allergies, nutrigenomics, and neuropsychol-
ogy of food choice. Research involving medical inter-
ventions such as MRI and other technologies requires 
critical ethical review. Human tissue samples might be 
required in pharmacokinetics and pharmacodynamic 
studies. In addition, observational studies involving 
large groups of consumers require prior consent from 
every participating individual. This could however po-
tentially make the research impossible. This prior con-
sent may not be required when research is being con-
ducted in public places such as restaurants, canteens 
and supermarkets. However, such researches need to 
address the issues related to consumer privacy, and 
this should be explained to both consenting and non-
consenting participants. On the other hand, research 
carried out in private homes, small social and cultural 
groups and hospitals requires rigorous prior informed 
consent, data confidentiality and privacy protection. 
In the case of identifiable data such as pictures, vid-
eos and audio recordings, informed consent should be 
obtained in respect of release of data to third parties. 
Where such consent is unavailable, participants should 
not be subject to disclosure of identifiable data per-
taining to themselves (46,47).
Studies involving covert research should only be 
done where collecting data by any other methods is 
impossible, where risks to participants are minimal, 
and where anonymity is guaranteed. These projects 
should undergo rigorous review by RECs. In addition 
to observational and covert studies, technological ad-
vance has paved the way for utilization of social me-
dia for data collection in food related research. This 
method might be of interest to people who want to 
avoid face-to-face interviews. However, special ethical 
consideration should be given to vulnerable groups like 
children and teenagers. Other ethical concerns in this 
regard arise in respect of recruitment, consent, privacy 
and authenticity of the data (47).
Mostly, food related research is multicentre and 
multidisciplinary. It is carried out in many countries, 
and might include working in developing countries. 
This requires the establishment of principles of equal-
ity and benefit to the local population, as well as the 
assurance of biological diversity with respect to shar-
ing of the benefits of genetic resources as food prod-
ucts and/or nutraceuticals. Specifically, when research 
is carried out in hazardous situations, the health and 
safety potential risks to researchers and local partici-
pants must be identified. In addition, security and con-
fidentiality of data must be ensured (47,48).
Ethical concerns related to nutrigenomics, functional, 
nano-based and genetically-modified (GM) foods
Nutrigenomics is based on the effect of nutri-
tion on gene expression related to health. This helps 
to identify the response of individuals to a particular 
diet that allows personalization of dietary regimes in 
order to obtain maximum health benefits thus leading 
to the development of commercial functional foods. A 
potential conflict may arise in this regard between the 
requirements of genetic data and non-medical data. 
Therefore, all types of data collection should be un-
der strict ethical control. Furthermore, nanotechnol-
ogy, nutrigenomics and genetic engineering, deployed 
to develop functional consumer oriented foods that 
require clinical trials, may give rise to various ethical 
concerns such as health claim labelling (EU regula-
tion No. 1924/ 2006) to ensure consumer satisfaction 
in terms of safety and choice of foods. Based on ethi-
cal concepts and arising from misconceptions regard-
ing nano-based and GM foods, these foods must be 
labelled with a ‘clinically tested to be safe’ statement 
(47-49).
Specifically, proper risk assessment of nano-based 
foods should be conducted in terms of consideration 
of potential health hazards such as biotoxicity and 
bioaccumulation in human tissues. Therefore, check-
ing the safety of such foods is of utmost importance. 
Moreover, in the case of animal involvement in a study, 
relevant ethical procedures should be implemented in-
cluding the development of in vitro procedures wher-
ever feasible.
Ethical issues in food security, sustainable food 
production and distribution.
Food security legislation primarily focuses on en-
suring sustainable production, distribution and mar-
keting of food, in adequate amounts to make it physi-
cally, socially and economically accessible, in order to 
meet the dietary requirements and food choices of all 
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people of the world, and thereby to reduce hunger and 
safeguard survival. However, despite efforts in this 
field, approximately 900 million people are chronically 
hungry and up to two billion suffer from intermittent 
food insecurity. It is therefore necessary to consider the 
ethical questions surrounding the integration of nutri-
tion into the food security concept. Key ethical issues 
include, but are not limited to, making societal deci-
sions and defining values of food security that have an 
impact on nutritional outcomes, and the ethical bal-
ance between environmental sustainability and meet-
ing individual dietary and nutritional requirements. Is-
sues related to overgrazing, extensive farming putting 
animals at risk, use of alternative protein resources and 
corresponding public acceptance issues make the situ-
ation even more cumbersome. Hence, such complex 
issues should be given thorough consideration to en-
sure global food security (46-49).
EU’s new legislations and competitiveness of Italy 
in Clinical Research 
Good clinical practice and fair clinical trials are 
integral components of health based research. In an 
effort to simplify and standardize the rules and regu-
lations of clinical trials across the EU, the European 
Clinical Trials Directive 2001/20/CE (ECTD) was 
introduced in 2001. The ECTD stressed good clinical 
practice and ethical values, to ensure the safety of trial 
participants (17).
Despite the fact that ECTD was an evolutionary 
approach, it failed to achieve its aims, as each member 
state was permitted to follow the ECTD guidelines 
autonomously. That made room for contradictory deci-
sions by competent local authorities. As a result, each 
member state has its own procedures for submission 
and processing of the proposals. It specifically affected 
sponsors that aimed to conduct multicentre trials in 
different member states, which obliged them to submit 
different applications in different members states, and 
sometimes in each centre (49,50). This considerably 
increased the time required for processing and approv-
al of applications and for conducting the trials. Besides 
that, compulsory insurance cover for trials and higher 
management costs led to a tremendous increase in the 
overall expenses of trials, making them unaffordable 
for independent research organisations and not-for-
profit institutes (50-52).
Consequently, the EU became less attractive for 
the pharmaceutical market, thus significantly reduc-
ing the number of CTs (53-55). The situation became 
even worse for Italy, which, despite being Europe’s 
third largest bio-pharmaceutical market with out-
standing research and leadership in the medical mi-
lieu, witnessed a marked decline in CTs. As a result 
of the ECTD, a lack of interest from sponsors, scar-
city of public funds for clinical trials and multiplicity 
of Ethics Committees, there was a record decrease in 
CTs (56,57). For instance, Italy recorded a 21% re-
duction in CTs from 2008 to 2012 (58). According to 
EudraCT (EU clinical trial database), Italy’s share of 
total projects registered in the US National Institute 
of Health’s (NIH) database has decreased from 18.5% 
in 2008 to 17.7% in 2012, in contrast to the rest of the 
EU member states (59,60).
This decrease in registered multicentre trials 
might be in part due to the cumbersome administra-
tive procedures required for submission of documents, 
review and approval of trials and signing of contracts 
after approval of CTs by independent ECs. For in-
stance, a survey was conducted on 134 Italian Inde-
pendent ECs, for a single trial by Porcu et al., 2008 
(61). This revealed that there is a huge variation in the 
application procedures for CTs with respect to the 
number and the format of required documents, with 
the number of necessary documents ranging from 6 
to 21, with 57% of the surveyed ECs requiring at least 
one personalized document. The number of hard cop-
ies required ranged from 6 to 249, while 26.9% of ECs 
demanded e-mail or CD-ROM submission (number 
of copies ranging from 1 to 15) as well as the paper 
version (61). This lack of harmonization in internal 
procedures and guidelines was further reported by an-
other study conducted in 2009 where a survey on the 
practice of ethics committees in 10 European coun-
tries was conducted (62).
As per the EFGCP report (2012), this variation 
in “centre-specific” documentation in Italy was largely 
due, to the high number of Independent ECs. Italy 
had the highest number of national, local and regional 
ECs when compared to the rest of the EU member 
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states. The high number of IECs resulted in a confus-
ing situation, particularly for the acceptance or refusal 
of an opinion. With respect to number of ECs. Italy 
had 260 ethics committees, the United Kingdom had 
120, Germany 50 and France only 25 (63).
Italy ranked last among nine EU countries with re-
spect to the number of NIH-registered trials per capita 
in a SAT-EU study conducted by Marta Gehring and 
co-workers in 2015. This ranking was based on surveys 
distributed to pharmaceutical companies, medical de-
vice manufacturers, Clinical Research Organizations 
and academic Clinical Trial Units (CTUs) (64,65). 
Italy scored low in all four of the criteria tested, i.e. 
ranking 10th out of 12 countries in the availability of 
trial-related information, 12th on the predictability and 
speed of ECs/ IRBs, and 9th on the availability of re-
quired equipment. It ranked 7th out of 9 on its general 
attractiveness as a place to conduct clinical trials. This 
low score assigned by highly ranked market partici-
pants with decision making power in trial investments 
is an alarming situation for a country with a history of 
scientific excellence. With respect to the setting up of 
multicentre trials, the participants were of the opinion 
that the EC’s procedures and contracting processes in 
Italy are so painstaking and sluggish, that, by the time 
an international multicentre trial is under way, the Ital-
ian site could still be in process of setting up. That is 
the main reason that, despite a desire to include Italy 
in the conduct of CTs, they do not participate (66). 
The study concluded that the reasons for this lack of 
interest in CTs in Italy are the bureaucratic proce-
dures, penalizing the high scientific level and research 
standards of the Italian Investigators (67). This is more 
apparent in the case of independent research organisa-
tions that usually takes longer to establish trials, have 
limited financial resources, and involve professionals 
who do not have the benefit of permanent employ-
ment contracts (67-70).
The SAT-EU Study Group suggested that the 
implementation of simplified legislation governing 
CTs, reduction in the number of ECs, consistency in 
contracts and the establishment of qualified CTUs will 
enhance international interest in setting up CTs, thus 
improving the status of clinical research in Italy (64,66). 
Nonetheless, the implementation of the ECTR (re-
placing ECTD; Regulation (EU) N.536/2014 of the 
European Parliament and of the Council on clinical tri-
als on medicinal products for human use’ adopted on 16 
April 2014 (11)) that aims to speed up the application 
process by centralizing, synchronizing and simplifying 
the administrative documentation for multicentre CTs 
across the EU, will definitely improve the situation in 
member states (71). The new ECTR has very ambi-
tious goals: to push Europe to be more competitive in 
the CTs scenario, to improve transparency, to create 
a simplified regulatory system and to increase public 
trust (55,71).
Proper implementation of any ethical legislation 
depends upon the awareness of the public in general 
and concerned people (management staff, researchers, 
reviewers, participants, ECs, investors etc) in partic-
ular. For instance, if researchers are not aware of the 
rules and regulations regarding ethical issues pertain-
ing to their research, they will not be able to meet the 
requirements set by the ECs in line with national and 
international standards. This will result in potential de-
lays in obtaining opinions from the concerned ECs. 
The same is the case regarding the proper utilization of 
the benefits of ECTR.
Recently in a study, two separate surveys addressed 
to Clinical Research coordinators (CRCs) and Clinical 
Investigators (CI) were conducted by Cagnazzo et al., 
(2017) in an attempt to investigate the perception and 
knowledge of the new regulations (ECTR) by Italian 
professionals (72). The study highlighted that the in-
stitutional channels and the managements of Hospi-
tals/Institutes are not taking appropriate measures to 
inform clinical researchers about the ECTR, and nei-
ther have they documented plans to do so; acquiring 
this information is still very much a personal initia-
tive of the researchers. Moreover, they highlighted that 
slow bureaucracy, inadequate English language skills 
and low susceptibility to change accounts for Italy be-
ing not ready to accommodate changes brought by 
ECTR (72).
Role of internal ethics committees in expediting the 
approval process of a research project
Be it clinical research, an observational study, food 
science and nutrition or biotechnological research, the 
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potential harm to human subjects and to animals in 
particular, and to the overall environment in general 
has necessitated the development of certain ethical 
guidelines to ensure that a project is conducted ac-
cording to national and international ethical standards. 
However, implementation of these guidelines, policies 
and procedures begins at the investigator and research-
er level. In most cases, potential delays in obtaining an 
opinion on a particular project from the responsible 
EC are in part due to inappropriate documentation, 
which in turn is due to lack of knowledge and experi-
ence in addressing the ethical issues (73,74). Setting up 
an internal institutional ethics committee (IEC) holds 
promise here for not-for-profit organizations, as these 
internal committees could provide initial feedback on 
research proposals. This would help them to address 
critical ethical issues prior to the submission of pro-
posals to regional/ local or national ECs, thus consid-
erably reducing the time taken for obtaining a positive 
opinion, and saving funds and energy. However, this 
does not necessarily guarantee approval of proposals 
by ECs (74). In addition, internal ethics committees 
can advise on the training of investigators with respect 
to ethical issues in their field of research.
However, to really get the benefits of an IEC, 
the organization should ensure that it is comprised 
of trained individuals that are familiar with research 
settings. This would not only help them to guide the 
investigators/ researchers in the preparation of project 
proposals but would also enable monitoring of ongo-
ing research projects. This would in turn help the in-
stitution to identify potential gaps in implementing 
policies and procedures, and to impose sanctions for 
violations by investigators. However, the risks associ-
ated with these committees are the potential occur-
rence of conflicts of interest, and the personal likes and 
dislikes of members (75,76). Studies related to evalu-
ation of the role of IECs are scarce. Further studies 
in this regard might prove useful in determining their 
efficacy in non-for-profit institutions in implementing 
institutional, national and international ethical policies 
and guidelines in the preparation of research propos-
als, and also in the conduct of research that might raise 
ethical concerns regarding safety, wellbeing and rights 
of human subjects in particular, of experimental ani-
mals and the overall environment in general.
Conclusion
Ethical approval of research projects, observa-
tional studies and clinical trials is necessary in order 
to safeguard human rights and wellbeing, and to avoid 
potential harm to society, religious groups, vulnerable 
subjects and animals. Ethical review of research pro-
jects improves the scientific quality and authenticity of 
research. However, considerable difficulties are faced 
by investigators and investors in the process of get-
ting approval for setting up clinical trials or food re-
lated research, and this has potentially hampered the 
progress of this kind of research in countries having 
multiple regulator ECs at various levels. This neces-
sitates the need for reduction in the number of ECs, 
improvement of the rules and regulations for ethical 
requirements in food related research, observational 
and epidemiological studies, and simplification and 
standardisation of the procedures for the submission 
of multicentre and interdisciplinary research projects.
Administrative procedures in the approval and 
setting up of trials are compromising Italy’s reputation 
for high scientific standards in medicine and clinical 
research. Implementation of simplified legislation gov-
erning clinical trials, reduction in the number of ECs, 
standardisation of contracts, and improvement of trials 
management through adequate clinical trials units, can 
encourage clinical research in Italy.
In addition, review of research proposals prior to 
submission by internal institutional ethics committees 
holds the promise of reducing the time duration re-
quired for the processing of proposals. However, this 
does not guarantee a positive outcome from an EC 
committee review. Reduction in the number of ECs, 
centralization of submission procedures and further 
studies evaluating the efficacy of internal ethical com-
mittees in setting up and conducting clinical trials in It-
aly might help in simplifying ethical review procedures 
and enhancing Italy’s competitiveness with respect to 
the global market for clinical research. The main prob-
lem in Italy and Europe is the lack of common legisla-
tion that would coordinate all the European countries 
in the same manner. Furthermore, there are difficulties 
in the interactions among countries located in differ-
ent continents due to the high lack of homogeneity 
among systems. Finally, we took the Italian model as 
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an example, because an international committee based 
in Italy is going to be established for the laboratory 
EBTNA-LAB. In the future, we will produce other 
works and publications in order to address other issues 
regarding ethics committees.
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